It is an informal nickname for retatrutide, a powerful new tripleagonist weightloss medication that is still in clinical trials and not yet FDAapproved. This article explains what GLP3 really refers to, how retatrutide works, what the research shows so far
A 50 mg dose was associated with a higher occurrence of adverse effects apart from constipation compared to 3 mg, 7 mg, 14 mg, and 25 mg doses
Erratum in: Signal Transduct Target Ther
The addition of glucagon receptor activation increases energy expenditure and fat oxidation beyond what GLP-1 alone can achieve
Unlike pharma conglomerates that research everything from oncology to immunology, Novo Nordisk concentrates on what it knows best
Its extended half-life reduces the frequency of administration, improving patient compliance